Friday - April 10, 2026

Category Archives: Science

ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “ALK+ NSCLC Pipeline Insight 2025” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK+ NSCLC pipeline landscape. It covers the ALK+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “NK Cell Therapies Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “RNA Interference Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Familial Hypercholesterolemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “Familial Hypercholesterolemia Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Familial Hypercholesterolemia pipeline landscape. It covers the Familial Hypercholesterolemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Wet Age-Related Macular Degeneration Market Forecast to 2034: Outlook Therapeutics’ FDA Setback and the Future of Therapies | DelveInsight

DelveInsight’s “Wet AMD – Market Insight 2034” covers the 7MM market with key players like Opthea, Outlook, Kodiak, Regenxbio, and IVERIC bio, highlighting emerging therapies and growing patient demand, while sparking curiosity about which next-generation treatment could redefine Wet AMD … Continue reading →

TCR Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “TCR Therapy Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Polycythemia Vera Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Polycythemia Vera Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the Polycythemia Vera pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

COVID-19 Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “COVID-19 Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment … Continue reading →